Investment Thesis
Johnson & Johnson is positioned to capitalize on secular trends in Healthcare. Our analysis suggests the market is underappreciating the margin expansion story.
[Source: Generated via Semantic Analysis of JNJ 10-K filings]
Financial Summary (USD Millions)
| Fiscal Year |
2023A |
2024A |
2025E |
| Revenue |
388.2 |
419.51 |
453.33 |
| EBITDA |
38.53 |
34.27 |
44.51 |
| Net Income |
12.84 |
8.93 |
14.66 |
| EPS |
12.84 |
8.93 |
14.66 |
Valuation Methodology
Our valuation is derived from a 10-year DCF model using a WACC of 9.0% and a terminal growth rate of 2.5%. We also consider EV/EBITDA multiples relative to the Healthcare peer group.
Key Risks
- Cyclical downturn in Healthcare.
- Regulatory changes affecting margins.
- Execution risk on new product launches.
AUDIT TRAIL
Model ID: 92b5c060-40c7-40ac-b74f-1a0fddab6306
Version: FinGPT-v4.2
Training Cutoff: 2025-10-31
Compliance Check: PASS
Processing Time: 155ms
Disclaimer: This report is generated by an autonomous AI system for informational purposes only. It does not constitute financial advice. Past performance is not indicative of future results.